Product Program year 2025 Source: CMS Open Payments

Invega Sustenna

Drug Neuroscience

NDC 50458-560-01

Open in the dashboard

General payments

$19,917,288

231,829 payments

Research payments

$3,930,225

38 payments

Through program year 2025, $19,917,288 in general payments and $3,930,225 in research payments were reported against Invega Sustenna (Neuroscience).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

13 rows
Year Kind Amount Payments
2025 General $3,964,394 39,711
2024 General $4,559,796 41,628
2024 Research $1,054,467 5
2023 General $3,545,996 42,202
2023 Research $1,240,702 4
2022 General $2,990,345 39,531
2022 Research $856,918 8
2021 General $2,328,823 34,213
2021 Research $424,071 6
2020 General $741,652 10,460
2020 Research $95,007 5
2019 General $1,786,283 24,084
2019 Research $259,060 10

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $19,596,332 230,802 payments
  2. Janssen Scientific Affairs, LLC $312,390 921 payments
  3. Johnson & Johnson Health Care Systems Inc. $5,982 40 payments
  4. Janssen Biotech, Inc. $2,057 45 payments
  5. Johnson & Johnson Surgical Vision, Inc. $224 10 payments
  6. Abiomed $181 6 payments
  7. Actelion Pharmaceuticals US, Inc. $77 3 payments
  8. Ethicon US, LLC $46 2 payments
Top recipients General payments · program year 2025
  1. Franklin Cline Physician Assistant · Sacramento, CA $109,665 3% · 145 payments
  2. Carolyn Rekerdres Psychiatry · Dallas, TX $108,666 3% · 109 payments
  3. Sanford Herman Psychiatry · Jamaica, NY $107,915 3% · 139 payments
  4. Henry Nasrallah Psychiatry · Cincinnati, OH $104,822 3% · 92 payments
  5. Mark Reynolds Psychiatry · Durham, NC $103,412 3% · 81 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Psychiatry Psychiatry & Neurology $1,979,549 52% · 2,825 practitioners
  2. Nurse Practitioner, Psychiatric/Mental Health Nurse Practitioner $1,118,547 29% · 5,466 practitioners
  3. Physician Assistant $237,799 6% · 697 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $164,085 4% · 1,125 practitioners
  5. Nurse Practitioner $87,688 2% · 403 practitioners

The top 5 of 119 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $562,303 14% · 1,376 recipients
  2. New York $391,425 10% · 701 recipients
  3. Pennsylvania $341,272 9% · 641 recipients
  4. Florida $337,713 9% · 1,084 recipients
  5. North Carolina $259,455 7% · 380 recipients

The top 5 of 53 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

553,697

Prescriptions dispensed, refills included

Drug cost

$1,666,567,920

Paid at the pharmacy, in all

Medicare Part D drugs matched to INVEGA SUSTENNA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Invega Sustenna Paliperidone Palmitate Same name 14,010 551,596 $1,665,583,552
Invega Paliperidone Similar name 143 2,101 $984,368

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 198 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Jon Highum Psychiatry CA 644 $2,229,103 $27
Gabriel Crawford Nurse Practitioner MO 641 $2,246,411 None on record
Sharon Blue Nurse Practitioner FL 600 $1,761,510 None on record
Naveed Mirza Psychiatry MO 572 $1,757,388 None on record
Brett Gurkin Psychiatry NC 568 $1,852,355 $267

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 198 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to INVEGA SUSTENNA
Billing code Providers Services Paid by Medicare
Injection, paliperidone palmitate extended release, 1 mg J2426 6 47,084 $449,295

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

231,829 general · 38 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record